Our health and technology research looks at improving health and wellbeing through innovative technologies, as well as how to overcome health inequalities globally, against a backdrop of challenges and growing complexity.
Fleming Initiative
The Fleming Initiative was established by Imperial College London and Imperial College Healthcare NHS Trust to bring together research scientists, policymakers, clinicians, behavioural experts and partners to provide equitable solutions to antimicrobial resistance (AMR). Three new partners – LifeArc, Cepheid and Optum – have pledged additional funding and resources to the initiative, to tackle this growing global health threat.
"The Fleming Initiative has a unique approach to tackling the multifaceted challenge on AMR: bringing together world-class expertise in science, technology, policy and behavioural science alongside clinical experience." Professor the Lord Darzi of Denham, Chair of the Fleming Initiative
Unlocking a cure for Parkinson's
Researchers at Imperial have started a major new project to understand Parkinson’s disease more deeply than ever before. The Landmark Project will analyse hundreds of tissue samples from the Parkinson’s UK Brain Bank based at Imperial. Scientists hope to create a detailed map of how the disease affects genes in different cell types. This data will identify predictive biomarkers that could lead to new treatments.
Research on Alzheimer’s disease
Imperial is the only institution in the UK to have two Dementia Research Institute Centres. One of our research teams, led by Professor Lefkos Middleton, has received a philanthropic gift from Gates Ventures to study Alzheimer’s disease. The three-year project will allow researchers to expand the collection of clinical, biological, psychosocial, cognitive and lifestyle measures for up to 12 years. This will create a valuable resource that could help predict a person’s risk of developing Alzheimer’s.
Prostate cancer scans
A new prostate cancer screening trial at Imperial, funded by Prostate Cancer UK, is aiming to save thousands of lives in the UK. The TRANSFORM trial will bring together top researchers to develop a new and more effective way to screen for prostate cancer, potentially reducing prostate cancer deaths by up to 40%.
ARIA funding
The UK’s Advanced Research and Innovation Agency (ARIA) is funding research that unlocks new methods to interface with the human brain. Earlier this year, four Imperial-led projects received almost £15 million towards cutting-edge research to help overcome neurodegenerative disease. Imperial receives the largest amount of funding from the ARIA of any institution.
“The School of Convergence Science (Health and Technology) is a bold initiative to harness the depth and breadth of our research to drive lasting societal impact and build a healthier, more equitable, and resilient future for all.” Professor Anthony Bull, School of Convergence Science Co-Director (Convenor)